Quantcast

Latest Immunosuppressive drug Stories

2008-08-21 18:00:53

COLUMBIA, Md., Aug. 21 /PRNewswire/ -- A recently published article by Sanchez-Velasco et al.* in Clinical Transplantation has expanded our understanding of the clinical potential of monitoring cell-mediated immunity in adult patients at risk for organ rejection or infection subsequent to kidney transplantation. Pablo Sanchez-Velasco and his colleagues in the Cantabria Health System and at the University of Cantabria, in Santander, Spain, used the Cylex ImmuKnow assay to prospectively...

2008-08-12 12:00:34

GAITHERSBURG, Md., Aug. 12 /PRNewswire/ -- MedImmune today announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus). The study is designed to assess the safety and tolerability of the antibody, also known as MEDI-545 in patients with moderately to severely active lupus, despite standard of care. Current treatment options for moderately to...

2008-08-12 12:00:34

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase 2A clinical trial is...

2008-07-30 09:01:27

WASHINGTON, July 30 /PRNewswire-FirstCall/ -- The ability of blood tests to precisely measure very low doses of anti-rejection drugs in kidney transplant patients may make a significant difference in assuring long-term viability and survival, according to research presented today at the American Association for Clinical Chemistry (AACC) annual meeting. The current thinking in transplant medicine favors reducing doses of tacrolimus and other immune-suppressive drugs as much as possible...

2008-07-09 09:00:12

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant...

2008-07-03 15:00:10

Chinese scientists say a treatment using several drugs targeting various parts of the immune system helps patients with severe lupus involving the kidneys. In our study, multitarget therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects, said Dr. Lei-Shi Li of the University School of Medicine in Nanjing, China. Lupus nephritis is inflammation of the kidneys occurring in patients with systemic lupus...

2008-06-01 18:00:06

TORONTO, June 1 /PRNewswire/ -- The final results of the Spare the Nephron (STN) study, a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil), showed the CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI). Furthermore, the study showed this improvement without increasing the risk of...

2008-01-23 06:00:54

Reportlinker.com announces that a new market research report related to the Health Care industry is available in its catalogue. Organ Transplant Immunosuppressive Markets To order that report: www.reportlinker.com/p075365/Organ-Transplant- Immunosuppressive-Markets.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) For more information, contact Nicolas by email nbo@reportlinker.com ,...

2006-10-25 21:00:35

Four Boston doctors had their research regarding the treatment of autoimmune disease reported in this week's New England Journal of Medicine (NEJM). Specifically Drs. Abdul Razzaque Ahmed, Zachary Spigelman, Lisa Cavacini and Marshall Posner reported on their use of rituximab and intravenous immune globulin in patients with recalcitrant pemphigus vulgaris. Pemphigus vulgaris is a potentially fatal autoimmune blistering disease that affects the skin and mucous membranes. It has been...

2006-01-12 22:29:03

NEW YORK (Reuters Health) - Use of inhaled cyclosporine, in addition to other immune-suppressing drugs in pill form, does not help prevent the early rejection of lung transplants, but it does seem to stave off long-term rejection and improve survival, according to a report in The New England Journal of Medicine. Conventional immunosuppressive drugs do not prevent long-term rejection after lung transplantation, lead author Dr. Aldo T. Iacono, from the University of Maryland in...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related